Exploring ways to target antioxidant pathways in lung cancer with specific mutations
Targeting antioxidant vulnerabilities in KEAP1/NRF2 mutant NSCLC
This study is looking at how changes in certain genes can make non-small cell lung cancer harder to treat with chemotherapy and radiation, and it aims to find new ways to improve these treatments for patients with those gene changes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-10929537 on NIH RePORTER |
What this research studies
This research investigates how mutations in the KEAP1 and NRF2 genes affect non-small cell lung cancer (NSCLC) and contribute to resistance against chemotherapy and radiation. By focusing on the antioxidant pathways regulated by NRF2, the study aims to identify specific enzymes that can be targeted to enhance the effectiveness of existing cancer treatments. The approach involves understanding the role of these enzymes in maintaining cellular balance and how they can be manipulated to overcome treatment resistance. Patients with these mutations may benefit from new therapeutic strategies developed through this research.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have mutations in the KEAP1 or NRF2 genes.
Not a fit: Patients without KEAP1 or NRF2 mutations or those with other types of lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with specific mutations in lung cancer, improving their response to chemotherapy and radiation.
How similar studies have performed: Other research has shown promising results in targeting antioxidant pathways in cancer treatment, suggesting that this approach may be effective.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Jiang, Chang — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Jiang, Chang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.